“cAMP-Specific” Phosphodiesterase Contributes to cGMP Degradation in Cerebellar Cells Exposed to Nitric Oxide
- 1 January 2001
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 59 (1) , 54-61
- https://doi.org/10.1124/mol.59.1.54
Abstract
Nitric oxide (NO) functions as a diffusible messenger in the central nervous system and elsewhere, exerting many of it physiological effects by activating soluble guanylyl cyclase, so increasing cellular cGMP levels. Hydrolysis of cyclic nucleotides is achieved by phosphodiesterases (PDEs) but the enzyme isoforms responsible for degrading cGMP in most cells have not been identified. We have devised a method for quantitatively monitoring the rate of breakdown of cGMP within intact cells and have applied it to rat cerebellar cell suspensions previously stimulated with NO. In contrast to previous findings in cultured cerebellar cells, there was no evidence from the use of selective inhibitors that PDE 1 participated importantly in cGMP hydrolysis. Moreover, procedures expected to increase PDE 1 activity by raising cytosolic Ca2+ concentrations (neurotransmitter agonists, Ca2+ ionophore) failed to influence cGMP breakdown. Instead, through the use of inhibitors selective for different PDE families, two isoforms were implicated: a “cGMP-specific” PDE (PDE 5), inhibited by sildenafil and zaprinast, and a “cAMP-specific” PDE (PDE 4), inhibited by low concentrations of rolipram and Ro-20–1724 and by milrinone. An explanation is offered for a participation of PDE 4 based on the high estimated intracellular cGMP concentration (∼800 μM) and the low affinity of the enzyme for cGMP. In accordance with predictions, recombinant PDE 4 was shown to hydrolyze high cGMP concentrations in a rolipram-sensitive manner. The widespread use of rolipram to test for a specific involvement of cAMP in cellular phenomena must therefore be questioned.Keywords
This publication has 34 references indexed in Scilit:
- Regulation of Nitric Oxide-Responsive Recombinant Soluble Guanylyl Cyclase by CalciumBiochemistry, 1999
- Association with the SRC Family Tyrosyl Kinase LYN Triggers a Conformational Change in the Catalytic Region of Human cAMP-specific Phosphodiesterase HSPDE4A4BJournal of Biological Chemistry, 1999
- Identification and Characterization of a Novel Family of Cyclic Nucleotide PhosphodiesterasesJournal of Biological Chemistry, 1998
- Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends in Pharmacological Sciences, 1997
- Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipramCellular Signalling, 1996
- Models of the diffusional spread of nitric oxide: Implications for neural nitric oxide signalling and its pharmacological propertiesNeuropharmacology, 1994
- Immunocytochemistry of cGMP in the Cerebellum of the Immature, Adult, and Aged Rat: the Involvement of Nitric Oxide. A Micropharmacological StudyEuropean Journal of Neuroscience, 1990
- Cellular Origins of Cyclic GMP Responses to Excitatory Amino Acid Receptor Agonists in Rat Cerebellum In VitroJournal of Neurochemistry, 1987
- Statistical Estimations in Enzyme KineticsEuropean Journal of Biochemistry, 1974
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973